These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18558606)

  • 1. LIPID abnormalities in patients infected with human immunodeficiency virus.
    Mikhail NE
    Endocr Pract; 2008; 14(4):492-500. PubMed ID: 18558606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid metabolism in treated HIV Infection.
    Dubé MP; Cadden JJ
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV protease inhibitors and dyslipidemia.
    Clotet B; Negredo E
    AIDS Rev; 2003; 5(1):19-24. PubMed ID: 12875104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
    Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
    Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blood lipid abnormalities during treatment with protease inhibitors].
    Vergès B; Petit JM
    Presse Med; 2001 May; 30(18):911-4. PubMed ID: 11413853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
    Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
    J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid lowering therapy in patients with HIV infection.
    McBride M; Chin MT; Lee SM; Kelly B
    Lancet; 1998 Nov; 352(9142):1782-3. PubMed ID: 9848377
    [No Abstract]   [Full Text] [Related]  

  • 11. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review.
    Souza SJ; Luzia LA; Santos SS; Rondó PH
    Rev Assoc Med Bras (1992); 2013; 59(2):186-98. PubMed ID: 23582562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
    Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
    Rahman AP; Eaton SA; Nguyen ST; Bain AM; Payne KD; Bedimo R; Busti AJ
    Pharmacotherapy; 2008 Jul; 28(7):913-9. PubMed ID: 18576906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
    Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
    Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy.
    Domingo P; Sambeat MA; Pérez A; Ordoñez J
    J Acquir Immune Defic Syndr; 2003 May; 33(1):114-6. PubMed ID: 12792364
    [No Abstract]   [Full Text] [Related]  

  • 17. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperlipidemia associated with protease inhibitor therapy.
    Echevarria KL; Hardin TC; Smith JA
    Ann Pharmacother; 1999; 33(7-8):859-63. PubMed ID: 10466916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class of antiretroviral drugs and the risk of myocardial infarction.
    ; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD
    N Engl J Med; 2007 Apr; 356(17):1723-35. PubMed ID: 17460226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.